Corrigendum to ‘MPN-395: efficacy and safety of ≤200 mg avapritinib in patients with advanced systemic mastocytosis : pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367-S368]: corrigendum - Radia, Deepti; Reiter, Andreas (Clinical lymphoma, myeloma & leukemia, 2022)
Online verfügbar: 31. Januar 2022, Artikelversion: 29. März 2022
Gesehen am 20.08.2024